<DOC>
	<DOC>NCT00491530</DOC>
	<brief_summary>The objective of the study is to assess the continued safety of the daily coadministration of ABT-335 in combination with rosuvastatin calcium, simvastatin or atorvastatin calcium.</brief_summary>
	<brief_title>A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Adult male and female subjects who voluntarily sign the informed consent. Subject has successfully completed the treatment phase of the preceding openlabel year 1 study. Subject is using or will use investigational medications, except as approved by Abbott. Subject has prematurely discontinued his/her combination therapy administered in the preceding openlabel year 1 study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>